Suicidalty in a placebo-controlled fluoxetine study of body dysmorphic disorder

International Clinical Psychopharmacology

Volumn 24, Issue 1, 2009, Pages 26-28

  Phillips, Katharine A ^a   Kelly, Megan M ^a  

^a BUTLER HOSPITAL   (United States)

Author keywords

Body dysmorphic disorder; Clinical trial; Dysmorphophobia; Fluoxetine; Suicidality; Suicide; Treatment

Indexed keywords

FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BODY DYSMORPHIC DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; PSYCHOLOGICAL ASPECT; SOMATOFORM DISORDER; SUICIDE;

DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS; SUICIDE; YOUNG ADULT;

EID: 58349107918     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32831db2e9     Document Type: Article

References (14)

1. FDA (2007). Revisions to product labeling. http://www.fda.gov/cderldrug/ antidepressants/antidepressants-label-change-2007.pdf
2. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ (2007). Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 164: 1044-1049.
3. Glanz L, Haas G. Sweeney J (1995). Assessment of hopelessness in suicidal patients. Clin Psychol Rev 15:49-64.
4. Hammad TA, Laughren T, Racoosin J (2006). Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339.
5. Jick H, Kaye JA, Jick SS (2004). Antidepressants and the risk of suicidal behaviors. JAMA 292:338-343.
6. Miller I, Bishop S, Norman W, Maddever H (1985). The modified Hamilton Rating Scale for Depression: reliability and validity. Psychiatry Res 14:131-142.
7. National Collaborating Centre for Mental Health (2006). OCD: core interventions in the treatment of OCD and body dysmorphic disorder. National Clinical Practice Guideline Number 31. London, British Psychiatric Society and Royal College of Psychiatrists.
8. NHS (2008). SSRIs (selective serotonin reuptake inhibitors): considerations. http://www.nhs.uk/Conditions/SSRIs-(selective-serotonin- reuptake-inhibitors)/Pages/Cautions.aspx?url=Pages/Considerations.aspx
9. Phillips KA (2006). An open-label study of escitalopram in body dysmorphic disorder. nt Clin Psychopharmacol 21:177-179.
10. Philips KA (2007). Suicidality in body dysmorphic disorder. Prim Psychistry 14:58-66.
11. Phillips KA, Albertini RS, Rasmussen SA (2002). A randomized placebocontrolled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 59:381-388.
12. Phillips KA, Hollander E (2008). Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image 5:13-27.
13. Phillips KA. Hollander E, Rasmussen SA, Aronowitz BR DeCaria C, Goodman WK (1997). A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull 33:17-22.
14. Simon GE, Savarino J (2007). Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 164:1029-1034.